Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
RAD-150
Also known as: TLB-150
RAD-150 is an esterified version of RAD-140, created to extend its half-life and improve bioavailability. It has essentially no published research and exists primarily in the grey market as a research chemical.
Risk Level
Very High RiskDifficulty
Advanced| Class | SARM |
| Category | SARMs |
Mechanism of Action
RAD-150 is a benzoate ester of RAD-140 that acts as a prodrug. Once in the body, the ester is cleaved to release active RAD-140. The ester modification extends the half-life and may improve oral bioavailability compared to the parent compound.
Dosing Research
No published research on dosing. Research community references 10-20 mg/day based on RAD-140 equivalence. Extended half-life compared to RAD-140. No established protocols.
Side Effects & Risks
Completely unknown safety profile. Presumed similar to RAD-140 (liver toxicity risk, hormonal suppression, cardiovascular strain) but with added uncertainty from the ester modification. Highest risk category due to zero published research.
Research Studies
Related compounds
Ostarine
SARMOstarine is the most widely studied SARM, originally developed for muscle wasting and osteoporosis. It has completed multiple Phase II and Phase III clinical trials, making it one of the few SARMs with substantial human data.
Ligandrol
SARMLigandrol is a non-steroidal SARM developed by Ligand Pharmaceuticals for muscle wasting conditions. It demonstrated significant lean mass gains in Phase I trials at doses as low as 1 mg/day.
Cardarine
OtherCardarine is not actually a SARM but a PPARδ agonist, often grouped with SARMs commercially. It was developed by GlaxoSmithKline for metabolic and cardiovascular diseases but was abandoned due to cancer findings in rodent studies.
RAD-140
SARMRAD-140 is a potent non-steroidal SARM developed by Radius Health. It has shown neuroprotective properties in preclinical studies and is currently in early clinical trials for breast cancer.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.